SCHEMBL9958264

SCHEMBL9958264

[c]1ccc(-c2nc(-c3ccccc3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.60
KMT2A Q03164 9/20 0.60
HPGD P15428 7/20 0.60
MAPT P10636 7/20 0.60
ALDH1A1 P00352 6/20 0.60
NTSR1 P30989 1/20 0.60
ADORA1 P30542 4/20 0.57
ADORA2A P29274 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 3/20 0.52
LMNA P02545 2/20 0.52
GLA P06280 1/20 0.51
TDP1 Q9NUW8 2/20 0.50
MAPK1 P28482 1/20 0.50
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP2C19 P33261 1/20 0.47
AGTR1 P30556 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9958067 0.89 MEN1 (0.50) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL713782 0.87 L3MBTL1 (0.56) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL438540 0.87 MEN1 (0.75) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL17367827 0.84 MEN1 (0.79) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL17367816 0.84 MEN1 (0.79) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL17970040 0.84 MEN1 (0.79) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL13113782 0.84 MEN1 (0.72) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL28268565 0.83 CYP19A1 (0.53) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL9920584 0.82 MEN1 (0.76) MEN1KMT2AHPGDMAPTALDH1A1
SCHEMBL17725321 0.82 MEN1 (0.76) MEN1KMT2AHPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MEN1 405/4885KMT2A 3592/4885HPGD 4413/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MEN1 405/4885KMT2A 3592/4885HPGD 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.